Mark Sheptoff Financial Planning LLC decreased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.1% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 14,940 shares of the biopharmaceutical company’s stock after selling 173 shares during the period. Mark Sheptoff Financial Planning LLC’s holdings in Gilead Sciences were worth $1,015,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Hall Laurie J Trustee boosted its stake in Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 250 shares during the last quarter. Cable Hill Partners LLC boosted its stake in Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 541 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. boosted its stake in Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 1,400 shares during the last quarter. Dubuque Bank & Trust Co. boosted its stake in Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 267 shares during the last quarter. Finally, Webster Bank N. A. boosted its stake in Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 624 shares during the last quarter. 74.02% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences, Inc. (GILD) traded up 0.35% during trading on Monday, hitting $72.36. The stock had a trading volume of 1,102,932 shares. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $82.10. The stock’s 50-day moving average price is $72.61 and its 200-day moving average price is $68.83. The company has a market capitalization of $94.50 billion, a P/E ratio of 7.86 and a beta of 1.21.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.45. The business had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company’s revenue for the quarter was down 8.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.08 EPS. Analysts expect that Gilead Sciences, Inc. will post $8.75 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be paid a $0.52 dividend. The ex-dividend date is Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.88%. Gilead Sciences’s dividend payout ratio is currently 22.58%.

COPYRIGHT VIOLATION WARNING: “Mark Sheptoff Financial Planning LLC Lowers Stake in Gilead Sciences, Inc. (GILD)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/21/mark-sheptoff-financial-planning-llc-lowers-stake-in-gilead-sciences-inc-gild.html.

GILD has been the subject of several analyst reports. BidaskClub cut Gilead Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Berenberg Bank reaffirmed a “buy” rating and issued a $86.00 price objective (up from $79.00) on shares of Gilead Sciences in a report on Sunday. Deutsche Bank AG reaffirmed a “buy” rating and issued a $81.00 price objective (up from $79.00) on shares of Gilead Sciences in a report on Thursday, July 27th. Leerink Swann reaffirmed a “hold” rating and issued a $74.00 price objective on shares of Gilead Sciences in a report on Tuesday, July 25th. Finally, Cowen and Company reaffirmed an “outperform” rating and issued a $90.00 price objective on shares of Gilead Sciences in a report on Thursday, July 27th. Eleven research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $80.64.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the transaction, the insider now directly owns 3,199,969 shares in the company, valued at approximately $227,197,799. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the completion of the transaction, the executive vice president now owns 106,113 shares in the company, valued at $8,051,854.44. The disclosure for this sale can be found here. Insiders sold a total of 206,666 shares of company stock worth $15,223,184 over the last 90 days. Insiders own 1.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.